Abstract The BRAFV600E mutation drives papillary thyroid carcinoma (PTC) progression and therapy resistance, yet its downstream effectors remain incompletely characterized.…
Abstract Papillary thyroid carcinoma (PTC) is the most common type of thyroid cancer, and patients with the BRAFV600E mutation often…
Abstract Background: Although high mobility group box protein 1 (HMGB1) has been researched in relation to cancer in many investigations,…
Abstract The APOBEC/AID family is known for its mutator activity, and recent evidence also supports the potential impact of ADARs.…
Abstract Background: BRAFV600E is the most common genetic mutation in differentiated thyroid cancer (DTC) occurring in 60% of patients and…
Abstract Finding effective treatments for cancer requires a thorough understanding of how it develops and progresses. Recent research has revealed…
Abstract Background: Whole-genome doubling (WGD) is a common mutation in cancer. Various studies have suggested that WGD is associated with…
Abstract Background: Insulin-like growth factor binding proteins (IGFBPs) are critical regulators of the biological activities of insulin-like growth factors. The…
Abstract Objective:BOLA2B is a recently discovered protein-coding gene. Here, pan-cancer analysis was conducted to determine the expression patterns of BOLA2B…
Abstract Papillary Thyroid Carcinoma (PTC) is characterized by unique tumor morphology, treatment response, and patient outcomes according to subtype and…